New Zeposia Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis Pharmaceutical Investing
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program Pharmaceutical Investing
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases Pharmaceutical Investing
Salix Will Present XIFAXAN , TRULANCE and RELISTOR Data at The American College of Gastroenterology 2022 Annual Scientific Meeting Pharmaceutical Investing
AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting Pharmaceutical Investing
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period Pharmaceutical Investing
European Commission Expands Merck's VAXNEUVANCE Indication to Include Infants, Children and Adolescents Pharmaceutical Investing
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities Pharmaceutical Investing
Merck's PREVYMIS Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation Life Science Investing News
